Cargando…

A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma

BACKGROUND: To date only a handful of drugs are available for the treatment of melanoma. Among them vemurafenib, a Braf(V600E) specific inhibitor, showed promising results in terms of response rate and increase in median survival time. However, its effectiveness is limited by development of resistan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhandaru, Madhuri, Ardekani, Gholamreza Safaee, Zhang, Guohong, Martinka, Magdalena, McElwee, Kevin J, Li, Gang, Rotte, Anand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051389/ https://www.ncbi.nlm.nih.gov/pubmed/24893747 http://dx.doi.org/10.1186/1471-2407-14-398

Ejemplares similares

Prognostic Significance of Nuclear Phospho-ATM Expression in Melanoma
por: Bhandaru, Madhuri, et al.
Publicado: (2015)

Decreased Expression of Nuclear p300 Is Associated with Disease Progression and Worse Prognosis of Melanoma Patients
por: Rotte, Anand, et al.
Publicado: (2013)

Stage-specific prognostic biomarkers in melanoma
por: Cheng, Yabin, et al.
Publicado: (2015)

Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis
por: Zhang, Guohong, et al.
Publicado: (2015)

High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma
por: Guo, Hongwei, et al.
Publicado: (2015)

Sox4 Mediated Dicer Expression is Critical for Suppression of Melanoma Cell Invasion
por: Jafarnejad, Seyed Mehdi, et al.
Publicado: (2012)

The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
por: Safaee Ardekani, Gholamreza, et al.
Publicado: (2012)

Nobel committee honors tumor immunologists
por: Rotte, Anand, et al.
Publicado: (2018)

C-Terminal Tensin-Like Protein Is a Novel Prognostic Marker for Primary Melanoma Patients
por: Sjoestroem, Cecilia, et al.
Publicado: (2013)

Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma
por: LU, JING, et al.
Publicado: (2015)

BRAF Mutation Analysis in Primary Acral Melanoma of 41 Cases from South of Iran
por: Sari Aslani, Fatemeh, et al.
Publicado: (2021)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
por: Sullivan, Ryan J., et al.
Publicado: (2011)

Cytoplasmic Pin1 expression is increased in human cutaneous melanoma and predicts poor prognosis
por: Chen, Xin, et al.
Publicado: (2018)

Expression of the RNase III enzyme DROSHA is reduced during progression of human cutaneous melanoma
por: Jafarnejad, Seyed Mehdi, et al.
Publicado: (2013)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma
por: Wu, Xiaowen, et al.
Publicado: (2017)

Cytoplasmic Skp2 Expression Is Increased in Human Melanoma and Correlated with Patient Survival
por: Chen, Guangdi, et al.
Publicado: (2011)

Addressing the age-old question of old age
por: McElwee, Joshua J
Publicado: (2004)

The Selection of Candidates for Trade School from a Group of Subnormal Italian Girls
por: McElwee, Edna Willis
Publicado: (1932)

An Analysis of the Binet Test of Naming Words
por: McElwee, Edna Willis
Publicado: (1932)

A Study of the Reading Attainment of Children in Ungraded Classes
por: McElwee, Edna Willis
Publicado: (1931)

Connecting the P300 to the diagnosis and prognosis of unconscious patients
por: Li, Ran, et al.
Publicado: (2015)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
por: Meevassana, Jiraroch, et al.
Publicado: (2022)

A BRAF mutation-associated gene risk model for predicting the prognosis of melanoma
por: Huang, Xiang, et al.
Publicado: (2023)

Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion
por: Khosravi, S, et al.
Publicado: (2014)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011)

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma
por: Sevilla, Arrate, et al.
Publicado: (2020)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF inhibitors: resistance and the promise of combination treatments for melanoma
por: Griffin, Merope, et al.
Publicado: (2017)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
por: Rotte, Anand
Publicado: (2019)

Formylation of Amines
por: Gerack, Ciera J., et al.
Publicado: (2014)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

The immune‐related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2014)

The immune-related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gi8eirkc0g4h4r92lk7l8inmqe